Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;22(3):2028-2032.
doi: 10.1111/jcmm.13448. Epub 2017 Nov 29.

Dihydroartemisinin up-regulates VE-cadherin expression in human renal glomerular endothelial cells

Affiliations

Dihydroartemisinin up-regulates VE-cadherin expression in human renal glomerular endothelial cells

Liqun Li et al. J Cell Mol Med. 2018 Mar.

Abstract

The antimalarial agent dihydroartemisinin (DHA) has been shown to be anti-inflammatory. In this study, we found that DHA increased the expression of the junctional protein vascular endothelial (VE)-cadherin in human renal glomerular endothelial cells. In addition, DHA inhibited TGF-β RI-Smad2/3 signalling and its downstream effectors SNAIL and SLUG, which repress VE-cadherin gene transcription. Correspondingly, DHA decreased the binding of SNAIL and SLUG to the VE-cadherin promoter. Together, our results suggest an effect of DHA in regulating glomerular permeability by elevation of VE-cadherin expression.

Keywords: TGF-β signalling; VE-cadherin; dihydroartemisinin; glomerular endothelial cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
DHA up‐regulates the expression of VE‐cadherin and inhibits TGF‐β signalling in HRGECs. (A) Relative VE‐cadherin mRNA expression in HRGECs treated with vehicle or DHA (n = 4; **< 0.01). (B) Immunoblots of VE‐cadherin protein from HRGECs treated with vehicle or DHA. GAPDH was used as loading control. (C) Representative images of VE‐cadherin immunostaining on HRGECs treated with vehicle or DHA. Magnification: 200X. (D) Immunoblots of TGF‐β RI protein from HRGECs treated with vehicle or DHA. (E) Immunoblots of phospho‐Smad2 and total Smad2 from HRGECs treated with vehicle or DHA (F) Immunoblots of phospho‐Smad3 and total Smad3 from HRGECs treated with vehicle or DHA. GAPDH was used as loading control.
Figure 2
Figure 2
DHA inhibits the expression of SNAIL/SLUG in HRGECs and suppresses SNAIL/SLUG binding affinity to the human VE‐cadherin promoter. HRGECs were treated with 25 μM DHA for 24 hrs before measurements. (A, C) Relative mRNA expression of SNAIL (A) and SLUG (C) measured by qRTPCR in HRGECs treated with vehicle or DHA (n = 4; **< 0.01). (B, D) Immunoblots of SNAIL (B) and SLUG (D) protein from HRGECs treated with DHA. GAPDH was used as loading control. (E, G) Representative images of PCR products from the DNA fragments pulled down by SNAIL (E) and SLUG (G) antibodies. Primers were designed to detect the ‐240 E‐box on the human VE‐cadherin promoter. (F, H) Binding ratios relative to the total input of chromatin used for ChIP with the SNAIL (F) and SLUG (H) antibodies (n = 4; **< 0.01).

Similar articles

Cited by

References

    1. Hausmann R, Grepl M, Knecht V, et al The glomerular filtration barrier function: new concepts. Curr Opin Nephrol Hypertens. 2012; 21: 441–9. - PubMed
    1. Obeidat M, Obeidat M, Ballermann BJ. Glomerular endothelium: a porous sieve and formidable barrier. Exp Cell Res. 2012; 318: 964–72. - PubMed
    1. Deen WM, Bridges CR, Brenner BM. Biophysical basis of glomerular permselectivity. J Membr Biol. 1983; 71: 1–10. - PubMed
    1. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006; 86: 279–367. - PubMed
    1. Molema G, Aird WC. Vascular heterogeneity in the kidney. Semin Nephrol. 2012; 32: 145–55. - PubMed

Publication types

MeSH terms